IL245468B - A modified t cell receptor, or antigen-binding fragment thereof, a therapeutic agent comprises the same and uses thereof - Google Patents

A modified t cell receptor, or antigen-binding fragment thereof, a therapeutic agent comprises the same and uses thereof

Info

Publication number
IL245468B
IL245468B IL245468A IL24546816A IL245468B IL 245468 B IL245468 B IL 245468B IL 245468 A IL245468 A IL 245468A IL 24546816 A IL24546816 A IL 24546816A IL 245468 B IL245468 B IL 245468B
Authority
IL
Israel
Prior art keywords
antigen
therapeutic agent
binding fragment
cell receptor
agent containing
Prior art date
Application number
IL245468A
Other languages
English (en)
Hebrew (he)
Other versions
IL245468A0 (en
Original Assignee
Univ Illinois
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Illinois filed Critical Univ Illinois
Publication of IL245468A0 publication Critical patent/IL245468A0/en
Publication of IL245468B publication Critical patent/IL245468B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IL245468A 2013-11-22 2016-05-04 A modified t cell receptor, or antigen-binding fragment thereof, a therapeutic agent comprises the same and uses thereof IL245468B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361907887P 2013-11-22 2013-11-22
PCT/US2014/066892 WO2015077607A1 (en) 2013-11-22 2014-11-21 Engineered high-affinity human t cell receptors

Publications (2)

Publication Number Publication Date
IL245468A0 IL245468A0 (en) 2016-06-30
IL245468B true IL245468B (en) 2020-10-29

Family

ID=53180203

Family Applications (2)

Application Number Title Priority Date Filing Date
IL245468A IL245468B (en) 2013-11-22 2016-05-04 A modified t cell receptor, or antigen-binding fragment thereof, a therapeutic agent comprises the same and uses thereof
IL245467A IL245467B (en) 2013-11-22 2016-05-04 A modified t cell receptor, or antigen-binding fragment thereof, a therapeutic agent comprising the same and uses thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL245467A IL245467B (en) 2013-11-22 2016-05-04 A modified t cell receptor, or antigen-binding fragment thereof, a therapeutic agent comprising the same and uses thereof

Country Status (20)

Country Link
US (4) US10023625B2 (enExample)
EP (2) EP3071594A4 (enExample)
JP (4) JP6697386B2 (enExample)
KR (2) KR102415259B1 (enExample)
CN (2) CN105899530B (enExample)
AU (4) AU2014352826B2 (enExample)
BR (1) BR112016011567A2 (enExample)
CA (2) CA2930852C (enExample)
DK (1) DK3071593T3 (enExample)
ES (1) ES2729406T3 (enExample)
IL (2) IL245468B (enExample)
MX (3) MX371202B (enExample)
PL (1) PL3071593T3 (enExample)
PT (1) PT3071593T (enExample)
RU (2) RU2740648C2 (enExample)
SA (1) SA516371174B1 (enExample)
SG (2) SG10201804335QA (enExample)
TR (1) TR201908404T4 (enExample)
WO (2) WO2015077607A1 (enExample)
ZA (2) ZA201603116B (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2626238C (en) 2005-10-17 2015-10-06 Memorial Sloan Kettering Cancer Center Wt1 hla class ii-binding peptides and compositions and methods comprising same
US9265816B2 (en) 2006-04-10 2016-02-23 Sloan Kettering Institute For Cancer Research Immunogenic WT-1 peptides and methods of use thereof
CA2861206C (en) 2012-01-13 2021-07-06 Richard J. O'reilly Immunogenic wt-1 peptides and methods of use thereof
US10815273B2 (en) 2013-01-15 2020-10-27 Memorial Sloan Kettering Cancer Center Immunogenic WT-1 peptides and methods of use thereof
CN110078813B (zh) 2013-01-15 2023-03-28 纪念斯隆凯特林癌症中心 免疫原性wt-1肽和其使用方法
EP3071594A4 (en) * 2013-11-22 2017-05-03 The Board of Trustees of the University of Illionis Engineered high-affinity human t cell receptors
CN108601849A (zh) * 2015-09-22 2018-09-28 尤利乌斯·马克西米利安维尔茨堡大学 一种在淋巴细胞中高水平的和稳定的基因转移的方法
CN114195882A (zh) * 2015-10-01 2022-03-18 圣拉斐尔医院有限公司 Tcr及其用途
GB201520570D0 (en) * 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
EP3394092A1 (en) 2015-12-23 2018-10-31 Fred Hutchinson Cancer Research Center High affinity t cell receptors and uses thereof
EP3475706B1 (en) * 2016-06-27 2021-08-11 Juno Therapeutics, Inc. Mhc-e restricted epitopes, binding molecules and related methods and uses
US11534461B2 (en) 2016-11-14 2022-12-27 Fred Hutchinson Cancer Center High affinity merkel cell polyomavirus T antigen-specific TCRS and uses thereof
EP3595708A4 (en) * 2017-03-15 2020-12-16 Fred Hutchinson Cancer Research Center HIGH AFFINITY MAGE-A1 SPECIFIC TCRS AND THEIR USES
IL270084B2 (en) * 2017-04-24 2026-03-01 Ospedale San Raffaele Srl TCR binding peptide from WILMS TUMOUR 1 protein and its use in cancer therapy
JP7181517B2 (ja) 2018-01-23 2022-12-01 国立大学法人三重大学 Ｔ細胞レセプター
AU2019312200B2 (en) * 2018-07-23 2024-11-14 Heidelberg Pharma Research Gmbh Use of anti-CD137 antibody drug conjugate (ADC) in allogeneic cell therapy
WO2020185796A1 (en) 2019-03-11 2020-09-17 Fred Hutchinson Cancer Research Center High avidity wt1 t cell receptors and uses thereof
GB201911066D0 (en) 2019-08-02 2019-09-18 Achilles Therapeutics Ltd T cell therapy
AU2020334064A1 (en) * 2019-08-20 2022-03-03 Fred Hutchinson Cancer Center T-cell immunotherapy specific for WT-1
CN115335404A (zh) * 2020-02-12 2022-11-11 艾伯维公司 双特异性结合分子
CN115461062A (zh) 2020-04-28 2022-12-09 阿基里斯治疗英国有限公司 T细胞疗法
CN112239495B (zh) * 2020-10-29 2022-04-12 上海药明生物技术有限公司 稳定的tcr结构及应用
US20240210396A1 (en) 2021-04-09 2024-06-27 Achilles Therapeutics Uk Limited Batch release assay for pharmaceutical products relating to t cell therapies
GB202109886D0 (en) 2021-07-08 2021-08-25 Achilles Therapeutics Uk Ltd Assay
AU2022299605A1 (en) 2021-06-22 2024-01-04 Achilles Therapeutics Uk Limited A method for producing antigen-specific t cells
CA3226965A1 (en) * 2021-07-19 2023-01-26 Board Of Regents, The University Of Texas System Peptides and engineered t cell receptors targeting fanci, rad51, and pbk antigens and methods of use
CN119220425A (zh) * 2023-07-28 2024-12-31 佳吾益(北京)科技有限公司 发现mhc新抗原肽表位的工程化细胞

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3927193A (en) 1973-05-18 1975-12-16 Hoffmann La Roche Localization of tumors by radiolabelled antibodies
US3939350A (en) 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4277437A (en) 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US4331647A (en) 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4348376A (en) 1980-03-03 1982-09-07 Goldenberg Milton David Tumor localization and therapy with labeled anti-CEA antibody
US4361544A (en) 1980-03-03 1982-11-30 Goldenberg Milton David Tumor localization and therapy with labeled antibodies specific to intracellular tumor-associated markers
US4444744A (en) 1980-03-03 1984-04-24 Goldenberg Milton David Tumor localization and therapy with labeled antibodies to cell surface antigens
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US4468457A (en) 1981-06-01 1984-08-28 David M. Goldenberg Method for producing a CSAp tryptic peptide and anti-CSAp antibodies
US5101827A (en) 1985-07-05 1992-04-07 Immunomedics, Inc. Lymphographic and organ imaging method and kit
US4640561A (en) 1985-11-15 1987-02-03 Ford Motor Company Flexible printed circuit connector
US5059413A (en) 1988-04-18 1991-10-22 Xoma Corporation Scintigraphic monitoring of immunotoxins using radionuclides and heterobifunctional chelators
JP3070763B2 (ja) 1989-08-09 2000-07-31 ロメッド インコーポレイティド テクネチウムまたはレニウムでの抗体または他のタンパク質の直接放射能標識
US5299253A (en) 1992-04-10 1994-03-29 Akzo N.V. Alignment system to overlay abdominal computer aided tomography and magnetic resonance anatomy with single photon emission tomography
US6696251B1 (en) 1996-05-31 2004-02-24 Board Of Trustees Of The University Of Illinois Yeast cell surface display of proteins and uses thereof
US6699658B1 (en) 1996-05-31 2004-03-02 Board Of Trustees Of The University Of Illinois Yeast cell surface display of proteins and uses thereof
US6300065B1 (en) 1996-05-31 2001-10-09 Board Of Trustees Of The University Of Illinois Yeast cell surface display of proteins and uses thereof
US6759243B2 (en) 1998-01-20 2004-07-06 Board Of Trustees Of The University Of Illinois High affinity TCR proteins and methods
BR9910253A (pt) 1998-05-19 2002-09-17 Avidex Ltd Receptor de célula t solúvel
WO2000023087A1 (en) 1998-10-21 2000-04-27 Sunol Molecular Corporation Polyspecific binding molecules and uses thereof
MXPA04001974A (es) 2001-08-31 2004-07-16 Avidex Ltd Receptor de celula t soluble.
US7892559B2 (en) 2002-01-30 2011-02-22 Survac Aps Survivin-derived peptides and use thereof
NZ539225A (en) 2002-10-09 2006-09-29 Avidex Ltd Single chain recombinant T cell receptors
GB0304068D0 (en) 2003-02-22 2003-03-26 Avidex Ltd Substances
GB0328363D0 (en) 2003-12-06 2004-01-14 Imp College Innovations Ltd Therapeutically useful molecules
JP4773434B2 (ja) 2004-05-19 2011-09-14 イムノコア リミテッド 高親和性ｎｙ−ｅｓｏｔ細胞受容体
EP1756278B1 (en) 2004-05-19 2008-09-17 MediGene Ltd. Method of improving t cell receptors
GB0524477D0 (en) 2005-11-30 2006-01-11 Avidex Ltd Isolated T cell receptors which specifically bind to vygfvracl-hla-24
GB0511124D0 (en) * 2005-06-01 2005-07-06 Avidex Ltd High affinity melan-a t cell receptors
AT503861B1 (de) 2006-07-05 2008-06-15 F Star Biotech Forsch & Entw Verfahren zur manipulation von t-zell-rezeptoren
WO2008039818A2 (en) 2006-09-26 2008-04-03 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Modified t cell receptors and related materials and methods
US9281917B2 (en) 2007-01-03 2016-03-08 Nokia Technologies Oy Shared control channel structure
CN102272153B (zh) * 2008-11-24 2015-04-15 德国慕尼黑亥姆霍兹研究中心健康和环境有限公司 高亲和力t细胞受体及其应用
WO2010075417A1 (en) * 2008-12-23 2010-07-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Survivin specific t cell receptor for treating cancer
CA2751762A1 (en) 2009-02-09 2010-08-12 Helmholtz Zentrum Muenchen Deutsches Forschungszentrum Fuer Gesundheit U Nd Umwelt (Gmbh) Repertoire of allo-restricted peptide-specific t cell receptor sequences and use thereof
GB0911566D0 (en) * 2009-07-03 2009-08-12 Immunocore Ltd T cell receptors
EP2486049A1 (en) 2009-10-06 2012-08-15 The Board Of Trustees Of The UniversityOf Illinois Human single-chain t cell receptors
CN103097407A (zh) 2010-07-28 2013-05-08 英美偌科有限公司 T细胞受体
AU2011304728A1 (en) 2010-09-20 2013-03-14 Biontech Ag Antigen-specific T cell receptors and T cell epitopes
CN107557334B (zh) 2012-05-03 2021-06-25 弗雷德哈钦森癌症研究中心 增强亲和力的t细胞受体及其制备方法
WO2014191465A1 (en) * 2013-05-28 2014-12-04 Møller Niels Iversen Peptides derived from lawsonia intracellularis and their use in vaccination
PL228457B1 (pl) 2013-08-30 2018-03-30 Univ Jagiellonski Tomograf hybrydowy TOF-PET/CT
EP3071594A4 (en) 2013-11-22 2017-05-03 The Board of Trustees of the University of Illionis Engineered high-affinity human t cell receptors
CA2956545A1 (en) 2014-08-04 2016-02-11 Fred Hutchinson Cancer Research Center T cell immunotherapy specific for wt-1
CN113105562B (zh) * 2018-09-26 2023-12-01 安源医药科技（上海）有限公司 突变型单链人凝血因子viii在制备融合蛋白中的应用

Also Published As

Publication number Publication date
WO2015077607A1 (en) 2015-05-28
US20220396606A1 (en) 2022-12-15
IL245467A0 (en) 2016-06-30
JP6697386B2 (ja) 2020-05-20
RU2016124179A (ru) 2017-12-27
JP2022023196A (ja) 2022-02-07
MX2016006620A (es) 2017-05-11
JP6970724B2 (ja) 2021-11-24
IL245467B (en) 2020-04-30
RU2729383C2 (ru) 2020-08-06
US20160280756A1 (en) 2016-09-29
AU2019272003A1 (en) 2019-12-19
PL3071593T3 (pl) 2019-11-29
EP3071594A4 (en) 2017-05-03
ZA201603116B (en) 2018-12-19
KR20160087866A (ko) 2016-07-22
ES2729406T3 (es) 2019-11-04
NZ719707A (en) 2020-09-25
CN105899530A (zh) 2016-08-24
JP2017501130A (ja) 2017-01-12
KR20160085345A (ko) 2016-07-15
JP6476182B2 (ja) 2019-02-27
PT3071593T (pt) 2019-06-27
JP2017501129A (ja) 2017-01-12
JP2020007374A (ja) 2020-01-16
CN105873945A (zh) 2016-08-17
EP3071593A4 (en) 2017-05-03
AU2019272003B2 (en) 2021-05-06
US10023625B2 (en) 2018-07-17
AU2014352834A1 (en) 2016-05-26
US20190055298A1 (en) 2019-02-21
ZA201603169B (en) 2020-05-27
EP3071594A1 (en) 2016-09-28
AU2014352826A1 (en) 2016-05-26
NZ719720A (en) 2020-09-25
SG10201804335QA (en) 2018-06-28
SA516371174B1 (ar) 2019-04-14
AU2014352826B2 (en) 2019-08-01
MX2016006625A (es) 2016-12-02
MX2021006932A (es) 2021-07-07
EP3071593B1 (en) 2019-03-13
CN105873945B (zh) 2020-07-17
AU2014352834B2 (en) 2019-08-29
TR201908404T4 (tr) 2019-07-22
DK3071593T3 (da) 2019-06-11
CA2930847A1 (en) 2015-05-28
IL245468A0 (en) 2016-06-30
BR112016011583A2 (pt) 2017-09-26
EP3071593A1 (en) 2016-09-28
KR102415259B1 (ko) 2022-06-30
CA2930852C (en) 2024-01-23
MX371202B (es) 2020-01-22
AU2021202274A1 (en) 2021-05-06
WO2015077615A1 (en) 2015-05-28
US10344075B2 (en) 2019-07-09
BR112016011567A2 (pt) 2017-10-24
CN105899530B (zh) 2020-05-08
CA2930852A1 (en) 2015-05-28
RU2016124163A (ru) 2017-12-27
US20160280755A1 (en) 2016-09-29
MX383471B (es) 2025-03-14
RU2740648C2 (ru) 2021-01-19
SG10201804330YA (en) 2018-07-30

Similar Documents

Publication Publication Date Title
IL246137A0 (en) Antibody pd-1, its antigenic binding part, and its medical use
IL258405A (en) Antibody/t-cell receptor chimeric constructs and uses thereof
DK2956175T3 (da) Kimærisk antigenreceptor og fremgangsmåder til anvendelse deraf
EP2976045A4 (en) METHOD AND DEVICES RELATED TO PATIENT-ADAPTED HIP-JOINT IMPLANTS
LT2958943T (lt) Vėžio gydymas, naudojant humanizuotą anti-egfrviii chimerinio antigeno receptorių
DK3039040T3 (da) Kimær anti cd30-antigenreceptor og anvendelse deraf
EP3315606C0 (en) ANTI-HUMAN TRANSFERRIN RECEPTOR ANTIBODIES CROSSING THE BLOOD-BRAIN BARRIER
DK3274366T3 (da) Kimær antigenreceptor
IL245467B (en) A modified t cell receptor, or antigen-binding fragment thereof, a therapeutic agent comprising the same and uses thereof
DK3508502T3 (da) Kombination af anti-lag-3-antistoffer og anti-pd-1-antistoffer til behandling af tumorer
DK2986304T3 (da) Farmaceutisk sammensætning, fremgangsmåder til behandling og anvendelser deraf.
EP3362110C0 (en) HEMOSTATIC DEVICE
HUE040234T2 (hu) Humanizált anti-CD134 (OX40) antitestek és felhasználásaik
BR112017011784A2 (pt) dispositivo de torniquete
EP2968852A4 (en) FISTLE RECEPTOR DEVICES AND METHOD THEREFOR
EP3455971A4 (en) FAST TRANSFER RECOVERY WITH SHORT LATEN TIME
EP2938252A4 (en) INTRAVASCULAR DEVICES, SYSTEMS AND METHOD
EP2912246A4 (en) IMPROVED ROTATING BLOCKING DEVICE
HUE040540T2 (hu) Módosított csukló régiót tartalmazó IgG4 Fc fragmens
EP2981939A4 (en) SYSTEMS, METHODS AND DEVICES FOR TRANSACTIONS
EP2964291A4 (en) SAFETY DEVICE
DK2981087T3 (da) Indretning til billeddekodning, fremgangsmåde til billeddekodning og program til billeddekodning
EP2967709A4 (en) THERAPEUTIC CRYOABLATION SYSTEM
EP3046475A4 (en) SHIELDING DEVICE FOR SHUTTER BLOCK
SG11201506358PA (en) Anti-cdh3 humanized antibody, drug conjugate thereof, and use thereof

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed